Selective IgA deficiency is the most common primary immunodeficiency in humans. It affects roughly 1 in 300-700 people of European descent, yet most people who have it are never diagnosed. The reason is straightforward: the majority of IgA-deficient individuals are asymptomatic, compensating through other immunoglobulin pathways without ever realizing their mucosal immune system has a gap. But for a significant subset, that gap has consequences. The gut is the body's largest mucosal surface, and IgA is its primary immune defense. When IgA is absent, the small intestine loses a critical mechanism for controlling bacterial populations, and the door to SIBO opens wider.
What is selective IgA deficiency?
Selective IgA deficiency is defined by the European Society for Immunodeficiencies (ESID) as a serum IgA level below 7 mg/dL (0.07 g/L) with normal serum IgG and IgM levels in a patient older than 4 years in whom other causes of hypogammaglobulinemia have been excluded. The condition is considered primary (genetic) in most cases, though the exact inheritance pattern is complex and involves multiple genes in the MHC region on chromosome 6. Partial IgA deficiency (serum IgA between 7 and 70 mg/dL, which is more than two standard deviations below the age-adjusted mean) is even more common but less well studied. The clinical significance of partial IgA deficiency is debated, though it may carry some of the same risks at lower severity.
How IgA protects the gut
IgA exists in two forms in the body. Serum IgA circulates in the bloodstream as a monomer. Secretory IgA (sIgA) is a dimer produced by plasma cells in the gut-associated lymphoid tissue, transported across the epithelium by the polymeric immunoglobulin receptor (pIgR), and released into the intestinal lumen coated with a secretory component that protects it from enzymatic degradation. The gut produces approximately 3-5 grams of sIgA per day, making it the most abundantly produced immunoglobulin in the body. In the intestinal lumen, sIgA performs immune exclusion: it binds bacteria, toxins, and antigens, preventing them from adhering to the mucosal surface and penetrating the epithelial barrier. It does this without activating complement or triggering inflammation, making it a uniquely non-destructive defense mechanism.
Why IgA deficiency promotes SIBO
Without sIgA in the intestinal lumen, bacteria can adhere to the small intestinal mucosa more effectively. They resist the sweeping action of the migrating motor complex more successfully when anchored to the mucosal surface. They can also form biofilms, which are structured bacterial communities that are significantly more resistant to both immune clearance and antibiotic therapy. The absence of sIgA also means that bacterial antigens reach the epithelial surface more readily, potentially triggering inflammatory responses that further disrupt the mucosal barrier. This creates a self-reinforcing cycle: immune deficiency allows overgrowth, overgrowth causes inflammation, inflammation damages the barrier further, and bacterial translocation increases. The 48% SIBO prevalence in IgA-deficient patients reflects this vulnerability.
The celiac disease connection
One of the most clinically important associations with selective IgA deficiency is celiac disease. IgA-deficient individuals have a 10-20 times higher risk of developing celiac disease compared to the general population. The prevalence of celiac disease in IgA deficiency is estimated at 10-20%, compared to approximately 1% in the general population. This association matters for SIBO patients on two levels. First, celiac disease itself is a risk factor for SIBO due to villous atrophy, altered motility, and changes in the intestinal environment. Second, the standard celiac screening test (tissue transglutaminase IgA, or tTG-IgA) will be falsely negative in IgA-deficient patients because it measures an IgA-based antibody that the patient cannot produce. If you are IgA-deficient, celiac screening must use IgG-based tests: tTG-IgG or deamidated gliadin peptide IgG (DGP-IgG).
⚠️If you have IgA deficiency, standard celiac blood tests (tTG-IgA) can give false-negative results. Ask your doctor to use IgG-based celiac tests (tTG-IgG or DGP-IgG) instead. Undiagnosed celiac disease in an IgA-deficient patient compounds SIBO risk.
Testing for IgA deficiency
Diagnosing selective IgA deficiency requires a simple blood test: a serum immunoglobulin panel measuring IgA, IgG, and IgM levels. The test is widely available, inexpensive, and covered by most insurance plans when ordered with clinical justification. A serum IgA below 7 mg/dL with normal IgG and IgM confirms the diagnosis in patients over 4 years of age. Results should be interpreted in context. A single low IgA result warrants confirmation with repeat testing. In patients under 4, IgA levels may still be maturing and should not be used for definitive diagnosis. If both IgA and IgG are low, the pattern suggests CVID rather than selective IgA deficiency, and referral to immunology is warranted.
Management approaches for IgA-deficient SIBO patients
Selective IgA deficiency has no cure. Immunoglobulin replacement therapy (IVIG or subcutaneous Ig) is not indicated for isolated IgA deficiency because it replaces IgG, not IgA. In fact, IgA-deficient patients can develop anti-IgA antibodies, and in rare cases, IVIG administration can trigger anaphylaxis. Management therefore focuses on treating SIBO when it occurs (rifaximin, herbal antimicrobials, or other targeted antibiotics), maintaining prokinetic support to optimize the migrating motor complex, monitoring for associated conditions (celiac disease, autoimmune thyroid disease, autoimmune hepatitis), vaccinating against encapsulated organisms (pneumococcal and meningococcal vaccines) to compensate for the mucosal defense gap, and considering serum immunoglobulin bovine supplementation, which has limited but emerging evidence for supporting mucosal immunity. Patients with frequent, severe infections or progression to CVID should be referred to clinical immunology.
- Treat SIBO episodes with appropriate antibiotics or herbal antimicrobials.
- Use prokinetic therapy to support the migrating motor complex and reduce relapse risk.
- Screen for celiac disease using IgG-based tests (tTG-IgG or DGP-IgG).
- Monitor for autoimmune conditions, particularly thyroid disease.
- Ensure pneumococcal and meningococcal vaccinations are current.
- Report any history of transfusion reactions to your physician (relevant for potential anti-IgA antibodies).
- Refer to immunology if infections are frequent, severe, or if IgG levels decline over time.
Frequently Asked Questions
Can IgA deficiency develop later in life or is it always present from birth?
Most cases are thought to be present from birth, though IgA levels normally do not reach adult levels until around age 4-7. There are reports of acquired IgA deficiency associated with certain medications (phenytoin, sulfasalazine) and infections, but these are less common. If you had a normal IgA level previously and it has dropped, your physician should investigate potential causes.
My IgA is low but not below 7 mg/dL. Does that still matter?
This is considered partial IgA deficiency. Its clinical significance is less clear than complete deficiency, but there is evidence that partial deficiency may carry some increased risk of infections and autoimmune conditions. If you have partial IgA deficiency and recurrent SIBO, it may be a contributing factor worth discussing with your doctor.
Can I take IgA supplements to fix the deficiency?
There are no IgA supplements available. Immunoglobulin replacement therapy provides IgG, not IgA. Some clinicians use serum-derived bovine immunoglobulin (SBI) supplements to provide supplemental immunoglobulins to the gut lumen, but the evidence for this approach is still emerging and it does not replace the specific function of secretory IgA.
⚠️This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.